Biopharming is the process of producing (or 'farming') medicinal compounds for therapeutic use using transgenic plants or animals. This entails putting target genes into hosts (crops or animals) that would not usually express them. The desired component may be expressed in a form that may be harvested on a regular basis (e.g., milk, eggs, fruits, etc.). The use of crops for bio-production of a recombinant protein (i.e., enzyme or antibody) or a system that includes bioreactors in vitro is referred to as biopharming. In comparison to industrial expenses, this approach provides great economic and health benefits, aided by new biotechnology methods that are improving. Plant biopharming is described as the cultivation of transgenic plants that have been genetically modified to produce "humanised" medicinal compounds for human use. "Molecular farming" is another term for biopharming. Corn, soybeans, rice, tobacco, and potatoes engineered to generate a material, usually a protein, vaccines, in their fruit, leaves, seeds, or tubers, are the most popular plants now being investigated for biopharming.
Title : Eliminating implant infection: 30,000 nanotextured implants in humans with no failure
Thomas J Webster, Interstellar Therapeutics, United States
Title : Information leakage: Types, remedies, and open problems
Julia Sidorova, Centro de Investigación Biomédica En Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
Title : Biotech innovations: Bioengineering potential for novel biomanufacturing systems
Murray Moo Young, University of Waterloo, Canada
Title : Development and characterization of exo-ITC: A fibrous bilayer exosome delivery system for dermatological applications
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Stem cell therapy: An affordable healthcare therapy for various diseases
Anant Marathe, Total Potential Cells (P) Ltd, India